Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1932 • ACR Convergence 2021
Identifying Clusters of Longitudinal Autoantibody Profiles Associated with Systemic Lupus Erythematosus Disease Outcomes
May Choi¹, Irene Chen², Ann Clarke³, Marvin Fritzler³, Katherine Buhler³, Murray Urowitz⁴, John Hanly⁵, Caroline Gordon⁶, Yvan St.Pierre⁷, Sang-Cheol Bae⁸, Juanita Romero-Diaz⁹, Francisco Sanchez-Guerrero¹⁰, Sasha Bernatsky¹¹, Daniel Wallace¹², David Isenberg¹³, Anisur Rahman¹⁴, Joan Merrill¹⁵, Paul R Fortin¹⁶, Dafna Gladman¹⁷, Ian N. Bruce¹⁸, Michelle Petri¹⁹, Ellen Ginzler²⁰, Mary Anne Dooley²¹, Rosalind Ramsey-Goldman²², Susan Manzi²³, Andreas Jnsen²⁴, Graciela Alarcn²⁵, Ronald van Vollenhoven²⁶, Cynthia Aranow²⁷, Meggan Mackay²⁷, Guillermo Ruiz-Irastorza²⁸, S Sam Lim²⁹, Murat Inanc³⁰, Kenneth Kalunian³¹, Sren Jacobsen³², Christine Peschken³³, Diane Kamen³⁴, Anca Askanase³⁵, David Sontag² and Karen Costenbader³⁶, ¹Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ²Massachusetts Institute of Technology, Cambridge, MA, ³University of Calgary, Calgary, AB, Canada, ⁴Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ⁵Dalhousie University, Halifax, NS, Canada, ⁶Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁷Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁸Hanyang University Medical Center, Seoul, Republic of Korea, ⁹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Federal District, Mexico, ¹⁰University Health Network/Sinai Health system, Toronto, ON, Canada, ¹¹McGill University, Montréal, QC, Canada, ¹²Cedars-Sinai, Los Angeles, CA, ¹³Centre for Rheumatology, University College London, London, United Kingdom, ¹⁴University College London, London, United Kingdom, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹⁷Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ¹⁸University of Manchester, Manchester, United Kingdom, ¹⁹Johns Hopkins University School of Medicine, Baltimore, MD, ²⁰SUNY Downstate Health Sciences University, Brooklyn, NY, ²¹Raleigh Neurology Associates, Chapel Hill, NC, ²²Northwestern University, Chicago, IL, ²³Allegheny Health Network, Wexford, PA, ²⁴Lund University, Lund, Sweden, ²⁵University of Alabama at Birmingham, Birmingham, AL, ²⁶Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ²⁷Feinstein Institutes for Medical Research, Manhasset, NY, ²⁸Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain, ²⁹Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ³⁰Istanbul University Faculty of Medicine, Istanbul, Turkey, ³¹UC San Diego, La Jolla, CA, ³²Copenhagen Lupus and Vasculitis Clinic, Centre for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ³³University of Manitoba, Winnipeg, MB, Canada, ³⁴Medical University of South Carolina, Charleston, SC, ³⁵Columbia University Medical Center, New York, NY, ³⁶Brigham and Women's Hospital, Belmont, MA
Background/Purpose: Prior studies of SLE clusters based on autoantibodies have utilized cross-sectional data from single centers. We applied clustering techniques to longitudinal and comprehensive autoantibody…
Abstract Number: 0076 • ACR Convergence 2021
Predicting the Transitions Between Lupus Anticoagulant Status and Thrombosis in SLE Using a Multi-state Markov Model
Selcan Demir¹, Jessica Li², Laurence Magder³ and Michelle Petri⁴, ¹Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Johns Hopkins University, Baltimore, MD, ³University of Maryland, Baltimore, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Antiphospholipid syndrome (APS) is a significant cause of morbidity and mortality in patients with SLE and lupus anticoagulant (LAC) positivity is the best predictor…
Abstract Number: 0267 • ACR Convergence 2021
Psychosocial and Health Measures in Systemic Lupus Erythematosus: Before and During the COVID-19 Pandemic in the Georgian’s Organized Against Lupus Cohort
Charmayne Dunlop-Thomas¹, Gaobin Bao¹, S Sam Lim² and Cristina Drenkard¹, ¹Emory University, Atlanta, GA, ²Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Disruptions of routines or livelihood and worry during the COVID-19 pandemic may have impacted systemic lupus erythematosus (SLE) patients in multiple ways. We explored…
Abstract Number: 0338 • ACR Convergence 2021
Serum and Urine Galectin-9, IP-10 and SIGLEC-1 as Biomarkers of Disease Activity in Patients with Systemic Lupus Erythematosus
Safak Mirioglu¹, Suzan Cinar², Omer Uludag³, Erdem Gurel³, Sibel Varelci³, Yasemin Ozluk⁴, Isin Kilicaslan⁴, Yasemin Yalcinkaya⁵, Halil Yazici⁶, Ahmet Gül³, Murat Inanc⁷ and Bahar Esen⁵, ¹Division of Nephrology, Bezmialem Vakif University School of Medicine, Istanbul, Turkey, ²Department of Immunology, Istanbul University Aziz Sancar Institute of Experimental Medicine, Istanbul, Turkey, ³Division of Rheumatology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey, ⁴Department of Pathology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey, ⁵Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ⁶Division of Nephrology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey, ⁷Istanbul University Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Galectin-9, interferon-inducible protein-10 (IP-10) and sialoadhesin (SIGLEC-1) are proteins associated with interferon signature, and considered as potential biomarkers reflecting disease activity in patients with…
Abstract Number: 0464 • ACR Convergence 2021
The Impact of Timely Post-Discharge Follow-up on Readmission Risk Among Patients with Systemic Lupus Erythematosus
Maria Schletzbaum¹, Nadia Sweet², W Ryan Powell², Andrea Gilmore Bykovskyi³, Farah Kaiksow², Ann Sheehy², Amy Kind² and Christie Bartels², ¹University of Wisconsin School of Medicine and Public Health, Middleton, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI, ³University of Wisconsin - Madison School of Nursing, Madison, WI
Background/Purpose: Systemic lupus erythematosus (SLE) has the 6th highest hospital readmission rate of all US chronic diseases with significant health disparities and costs. Transitional care…
Abstract Number: 0595 • ACR Convergence 2021
Lupus Nephritis Disparities Amongst Hospitalizations in the United States: A National Inpatient Sample Study
Sonia Gupta, Koree Willer, Amir Begovic, Mitch Waters, Laura Tarantino, Olufunmilayo Badejo, Ryan Walters and Theresa Townley, Creighton University School of Medicine, Omaha, NE
Background/Purpose: Black, Hispanic, and Native American populations in the US experience increased morbidity and mortality from systemic lupus erythematosus (SLE), with higher rates and worse…
Abstract Number: 0752 • ACR Convergence 2021
Intervening on Adverse Childhood Experiences in SLE—Self-Efficacy as a Potential Target
Kimberly DeQuattro¹, Andrea Seet¹, Laura Trupin², Stephanie Rush¹, Kamil Barbour³, Maria Dall'Era⁴, Jinoos Yazdany¹ and Patricia Katz¹, ¹University of California San Francisco, San Francisco, CA, ²UC San Francisco, San Francisco, CA, ³Centers for Disease Control, Atlanta, GA, ⁴University of California San Francisco, Corte Madera, CA
Background/Purpose: Modifiable adaptations to adversity such as resilience (the ability to recover from difficulty) and self-efficacy (the belief in one’s ability to succeed in a…
Abstract Number: 0863 • ACR Convergence 2021
Serum Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) and Cardiovascular Risk in Systemic Lupus Erythematosus: A Longitudinal Cohort Study
Chi Chiu Mok¹, Ling Yin Ho², Kar Li Chan³, Sau Mei TSE² and Chi Hung To⁴, ¹Tuen Mun Hospital, Hong Kong, China, ²Tuen Mun Hospital, Hong Kong, Hong Kong, ³Tuen Mun Hospital, Hong Kong, ⁴Pok Oi Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the predictive value of serum PCSK9 level on cardiovascular complications in Chinese patients with systemic lupus erythematosus (SLE).Methods: Consecutive patients who fulfilled…
Abstract Number: 0879 • ACR Convergence 2021
Anti-dsDNA Antibodies Increase Systemic Lupus Erythematosus Cardiovascular Risk Impairing the Immune and Cardiovascular Systems
Carlos Pérez-Sánchez¹, Alejandra Patiño-Trives², Maria Angeles Aguirre³, Laura Perez-Sanchez³, Chary Lopez-Pedrera³, Maria Luque-Tevar², Maria del Carmen Ábalos-Aguilera³, Iván Arias de la Rosa⁴, Cristobal Román-Rodriguez³, Pedro Segui³, Mario Espinosa³, Pilar Font³, Nuria Barbarroja⁴, alejandro Escudero³, Eduardo Collantes-Estevez³, Jose Antonio Gonzalez-Reyes⁵, Jose Manuel Villalba⁵ and Chary lopez-pedrera³, ¹IMIBIC, Córdoba, Spain, ²Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ⁴University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ⁵Department of Cell Biology, Physiology and Immunology, University of Córdoba, Campus de Excelencia Internacional Agroalimentario, ceiA3, Cordoba, Spain
Background/Purpose: This study aimed to delineate the role of anti-dsDNA antibodies on the alterations observed in the gene profile and the activity of immune and…
Abstract Number: 0956 • ACR Convergence 2021
Racial Disparities in Renal Outcomes over Time Among Hospitalized Children with SLE and Effects of Hospital Minority Composition
Joyce Chang¹, Cora Sears², Veronica Torres³ and Mary Beth Son¹, ¹Boston Children's Hospital, Brookline, MA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Temple University, Bucks County, PA
Background/Purpose: Racial and ethnic minorities are disproportionately affected by pediatric-onset SLE and have worse outcomes compared to their white counterparts. With ongoing advances in pediatric…
Abstract Number: 1048 • ACR Convergence 2021
Estimating the Weight of Rheumatologic Diseases in Mortality in Spain: Basic Cause of Death vs Multiple Cause Analysis
ana Perez¹, Fernando Albarran², Cristina Bohorquez², Atusa Movasat², Lucia Ruiz², Paula Pretel², elena Rabadan², Valentina Emperiale², Adrian abbasi³, julio suarez³, lorena montano³, emilio rico³, alfredo prieto⁴, Inmaculada Leon⁵, melchor Alvarez de Mon³ and beatriz perez⁶, ¹Hospital Universitario Príncipe de Asturias. Rheumatology. Medicine Faculty. Alcala University Department., Madrid, Spain, ²Hospital Universitario Príncipe de Asturias, Rheumatology Department, Alcala de Henares, ³Hospital Universitario Príncipe de Asturias, Madrid, Spain, ⁴Faculty of Medicine. Alcala University, Alcala de Henares, Spain, ⁵Communicable Diseases. Instituto de Salud Carlos III, Madrid, Spain, ⁶Department of Epidemiology of Chronic Diseases.National Center of Epidemiology/CIBERESP. Instituto de Salud Carlos III, Madrid, Spain
Background/Purpose: Classical statistics provide information on mortality rates for basic causes of death. Although many inflammatory rheumatic diseases decrease life expectancy, they are generally not…
Abstract Number: 1260 • ACR Convergence 2021
Factors That Impact Medication Adherence in Hospitalized Patients with Systemic Lupus Erythematosus
Prarthana Jain¹, Mithu Maheswaranathan², Holly Mitchell³ and Diane Kamen¹, ¹Medical University of South Carolina, Charleston, SC, ²Duke University School of Medicine, Durham, NC, ³Ralph H Johnson VA Medical Center, Charleston, SC
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease, characterized by episodes of flares, often involving multiple organ systems. Medication nonadherence remains a significant problem,…
Abstract Number: 1276 • ACR Convergence 2021
Predictors of Remission (on and off Treatment) and Lupus Low Disease Activity State (LLDAS) in Systemic Lupus Erythematosus (SLE): Data from a Multinational, Multicenter SLICC (Systemic Lupus International Collaborating Clinics) Cohort
Manuel Ugarte-Gil¹, Guillermo Ruiz-Irastorza², Dafna Gladman³, Murray Urowitz⁴, Ann Clarke⁵, John Hanly⁶, Caroline Gordon⁷, Sang-Cheol Bae⁸, Juanita Romero-Diaz⁹, Jorge Sanchez-Guerrero¹⁰, Sasha Bernatsky¹¹, Daniel Wallace¹², David Isenberg¹³, Anisur Rahman¹⁴, Joan Merrill¹⁵, Paul R Fortin¹⁶, Ian N. Bruce¹⁷, Michelle Petri¹⁸, Ellen Ginzler¹⁹, Mary Anne Dooley²⁰, Rosalind Ramsey-Goldman²¹, Susan Manzi²², Andreas Jnsen²³, Ronald F van Vollenhoven²⁴, Cynthia Aranow²⁵, Meggan Mackay²⁵, S Sam Lim²⁶, Murat Inanc²⁷, Kenneth Kalunian²⁸, Soren Jacobsen²⁹, Christine Peschken³⁰, Diane Kamen³¹, Anca Askanase³², Bernardo A. Pons-Estel³³ and Graciela Alarcn³⁴, ¹Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ²Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶Dalhousie University, Halifax, NS, Canada, ⁷Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁸Hanyang University Medical Center, Seoul, Republic of Korea, ⁹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Federal District, Mexico, ¹⁰Instituto Nacional de Ciencias Médicas y Nutrición, Inmunología y Reumatología, Mexico City, Mexico, ¹¹McGill University, Montréal, QC, Canada, ¹²Cedars-Sinai, Los Angeles, CA, ¹³Centre for Rheumatology, University College London, London, United Kingdom, ¹⁴University College London, London, United Kingdom, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹⁷University of Manchester, Manchester, United Kingdom, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁹SUNY Downstate Health Sciences University, Brooklyn, NY, ²⁰Raleigh Neurology Associates, Chapel Hill, NC, ²¹Northwestern University, Chicago, IL, ²²Allegheny Health Network, Wexford, PA, ²³Lund University, Lund, Sweden, ²⁴Amsterdam University Medical Centers, Department of Rheumatology and Clinical Immunology, Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ²⁵Feinstein Institutes for Medical Research, Manhasset, NY, ²⁶Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ²⁷Istanbul University Faculty of Medicine, Istanbul, Turkey, ²⁸UC San Diego, La Jolla, CA, ²⁹Rigshospitalet, Copenhagen, Denmark, ³⁰University of Manitoba, Winnipeg, MB, Canada, ³¹Medical University of South Carolina, Charleston, SC, ³²Columbia University Medical Center, New York, NY, ³³Grupo Oroo - Centro Regional de Enfermedades Autoinmunes y Reumticas (GO-CREAR), Rosario, Argentina, ³⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Remission and LLDAS have been proposed as the goals for the treatment of SLE patients. However, the predictors of each state remain unknown. The…
Abstract Number: 1292 • ACR Convergence 2021
Systemic Lupus Erythematous Readmissions Has Reduced in the Last Decade in the United States: A 9- year Longitudinal Study of the Nationwide Readmission Database
Ehizogie Edigin¹, Precious Eseaton², Chinenye Osuorji³, Ajayi Temitope⁴, Oluwafeyi Adedoyin⁵, Nneka Chukwu⁶ and Augustine Manadan⁷, ¹Internal Medicine, John H Stroger Jr. Hospital of Cook County, Chicago, IL, ²University of Benin, Benin, Nigeria, ³Internal Medicine, Burrell College of Osteopathic Medicine, Las Cruces, NM, ⁴Internal Medicine, University of Buffalo, Buffalo, NY, ⁵Internal Medicine, Englewood Hospital and Medicine Center, Englewood, NJ, ⁶Nuvance Health Internal Medicine Residency, Poughkeepsie, NY, ⁷Rush University Medical Center, Chicago, IL
Background/Purpose: Longitudinal data on trends of Systemic Lupus Erythematous (SLE) readmissions is scarce. Our study aims to study trends of 30-day readmissions of patients admitted…
Abstract Number: 1425 • ACR Convergence 2021
Voclosporin for Lupus Nephritis: Interim Analysis of the AURORA 2 Extension Study
Amit Saxena¹, Christopher Mela² and Antonia Coeshall³, ¹NYU School of Medicine, New York, NY, ²Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, ³Aurinia Pharmaceuticals Inc., Rockville
Background/Purpose: Voclosporin, a novel calcineurin inhibitor (CNI), has been tested successfully in 2 pivotal trials in adult patients with lupus nephritis (LN). Previously reported results…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].